A Phase I/II clinical trial for TCR modified T cells MDG1011in HR myeloid and lymphatic neoplasms (#799)
Laufzeit: 01.01.2019 - 31.12.2040
Kurzfassung
A phase I/II, open-label, non-randomized, multicentre, dose-escalation clinical trial with control group to evaluate the safety, feasibility and preliminary efficacy of PRAME TCR modified T cells, MDG1011, in subjects with high risk myeloid and lymphoid neoplasms
